ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 172 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2015. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $9,490,000 | -12.8% | 134,979 | -12.0% | 0.01% | -15.4% |
| Q3 2016 | $10,882,000 | +45.9% | 153,399 | +0.6% | 0.01% | +44.4% |
| Q2 2016 | $7,461,000 | -21.9% | 152,553 | +1.1% | 0.01% | -25.0% |
| Q1 2016 | $9,554,000 | -49.3% | 150,913 | -10.1% | 0.01% | -50.0% |
| Q4 2015 | $18,832,000 | +17.3% | 167,869 | +0.7% | 0.02% | +9.1% |
| Q3 2015 | $16,058,000 | +5.6% | 166,729 | +12.3% | 0.02% | +15.8% |
| Q2 2015 | $15,208,000 | +397.3% | 148,529 | +201.5% | 0.02% | +375.0% |
| Q1 2015 | $3,058,000 | +50.4% | 49,258 | +6.3% | 0.00% | +33.3% |
| Q4 2014 | $2,033,000 | -22.6% | 46,331 | -0.2% | 0.00% | -25.0% |
| Q3 2014 | $2,628,000 | +28.5% | 46,424 | +1.9% | 0.00% | +33.3% |
| Q2 2014 | $2,045,000 | +120.1% | 45,555 | +139.6% | 0.00% | +200.0% |
| Q1 2014 | $929,000 | – | 19,009 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |